Larvol Delta - Trial-in-Progress-A-Phase-3-Randomized-DoubleBlind-ActiveControl-Study-of-Pelabresib-DAK539-Plus-Ruxolitinib-vs-Placebo-Plus-Ruxolitinib-in-JAK-InhibitorNa239ve-Adult-Patients-With-Myelofibrosis-MANIFEST3

Jakafi (ruxolitinib) - Incyte

Jakafi XR (ruxolitinib XR) - Incyte

https://www.tradingview.com/news/tradingview:8d1ab02a07064:0-incyte-agrees-cms-pricing-deal-for-jakafi-avoids-certain-future-mandates-no-change-to-2026-guidance/

Sep 1, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next